Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

  • 1 Altmetric

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.

    Article  CAS  Google Scholar 

  2. Carr MJ, Sun J, DePalo D, et al. Talimogene laherparepvec (T-VEC) for the treatment of advanced locoregional melanoma after failure of immunotherapy: a multi-institutional experience. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10910-5.

    Article  PubMed  Google Scholar 

  3. Louie RJ, Perez MC, Jajja MR, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg. 2019;228:644–9.

    Article  Google Scholar 

  4. Franke V, Berger DMS, Klop WMC, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Int J Cancer. 2019;145:974–8.

    Article  CAS  Google Scholar 

  5. Long GV, Dummer R, Andtbacka RH, et al. Follow-up analysis of MASTERKEY-265 phase 1b (ph1b) study of talimogene laherparepvec (T-VEC) in combination (combo) with pembrolizumab (pembro) in patients (pts) with unresectable stage IIIB–IVM1c melanoma (MEL). Society for Melanoma Research Fifteenth International Congress, 24–27 October, 2018, Manchester, England.

Download references

Author information

Authors and Affiliations

  1. Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Michael J. Carr MD, MS & Jonathan S. Zager MD

  2. Department of Oncologic Sciences, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

    Jonathan S. Zager MD

Authors
  1. Michael J. Carr MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan S. Zager MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan S. Zager MD.

Ethics declarations

Disclosure

Jonathan S. Zager has advisory board relationships with Merck speaker’s bureau for Pfizer and Sun Pharma. He also receives research funding from Amgen, Delcath Systems, Philogen, Provectus and Novartis. In addition, he is a member of the speaker’s bureau for Amgen and SunPharma. Michael J. Carr has no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carr, M.J., Zager, J.S. ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy. Ann Surg Oncol 29, 802–803 (2022). https://doi.org/10.1245/s10434-021-10913-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10913-2

Search

Navigation